The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunotherapy era

doi:10.3877/cma.j.issn.1674-3253.2024.03.002

Abstract

Abstract:

Renal cell carcinoma (RCC) is one of the most common malignant tumors in the urinary systems, and the incidence of RCC has gradually increased. Metastatic RCC (mRCC) accounts for 13% of primary RCC, however, the prognosis of mRCC is extremely poor. Cytoreductive nephrectomy (CN) is the removal of primary tumor in patients with mRCC, and it has been the standard for patients receiving systemic cytokine therapy. With the development of targeted therapies and immunotherapies, the treatment outcome of mRCC has been significantly improved, and targeted therapies and immunotherapies have become frontline treatments for mRCC. Therefore, the role of CN in the management of patients with mRCC came into question in the targeted therapy and immunotherapy era. This article will try to describe the development process of CN in the treatment paradigm of mRCC, especially the latest progress in the targeted-immunotherapy era, as well as patient selection and timing of CN.

Key words: Metastatic renal cell carcinoma, Cytoreductive nephrectomy, Targeted therapy, Immunotherapy

Xing Huang, Lei Wang, Dan Xia. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunotherapy era[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(03): 208-213.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2024.03.002

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2024/V18/I03/208

References 36

[1]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1):17-48.
[2]	郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220.
[3]	Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer[J]. N Engl J Med, 2001, 345(23): 1655-1659.
[4]	Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon Alfa alone in metastatic renal-cell carcinoma: a randomised trial[J]. Lancet, 2001, 358(9286): 966-970.
[5]	Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma[J]. N Engl J Med, 2018, 379(5): 417-427.
[6]	Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma[J]. Eur Urol, 2019, 75(1): 111-128.
[7]	Psutka SP, Chang SL, Cahn D, et al. Reassessing the role of cytoreductive nephrectomy for metastatic renal cell carcinoma in 2019[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 276-283.
[8]	Larcher A, Fallara G, Rosiello G, et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines[J]. Eur Urol, 2020, 78(3): 321-326.
[9]	Figlin RA. Renal cell carcinoma: management of advanced disease[J]. J Urol, 1999, 161(2): 381-386.
[10]	Janiszewska AD, Poletajew S, Wasiutyński A. Spontaneous regression of renal cell carcinoma[J]. Contemp Oncol, 2013, 17(2): 123-127.
[11]	Milowsky MI, Nanus DM. Advanced renal cell carcinoma[J]. Curr Treat Options Oncol, 2001, 2(5): 437-445.
[12]	Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis[J]. J Urol, 2004, 171(3): 1071-1076.
[13]	Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma[J]. Urology, 2009, 73(2): 342-346.
[14]	Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy[J]. J Urol, 2007, 177(6): 1978-1984.
[15]	Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium[J]. Eur Urol, 2014, 66(4): 704-710.
[16]	Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study[J]. J Clin Oncol, 2016, 34(27): 3267-3275.
[17]	Petrelli F, Coinu A, Vavassori I, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis[J]. Clin Genitourin Cancer, 2016, 14(6): 465-472.
[18]	Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy[J]. J Urol, 2011, 185(1): 60-66.
[19]	Motzer RJ, Russo P. Cytoreductive nephrectomy - patient selection is key[J]. N Engl J Med, 2018, 379(5): 481-482.
[20]	Pierorazio PM, McKiernan JM, McCann TR, et al. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed[J]. BJU Int, 2007, 100(4): 755-759.
[21]	Barbastefano J, Garcia JA, Elson P, et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy[J]. BJU Int, 2010, 106(9): 1266-1269.
[22]	Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813.
[23]	Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290.
[24]	Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127.
[25]	Motzer R J, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1103-1115.
[26]	Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database[J]. Urol Oncol, 2020, 38(6): 604.e9-604.e17.
[27]	Bakouny Z, El Zarif T, Dudani S, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium[J]. Eur Urol, 2023, 83(2): 145-151.
[28]	Chen B, Li J, Huang Y, et al. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis[J]. Int J Surg, 2023, 109(4): 982-994.
[29]	Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma[J]. J Urol, 1997, 158(5): 1691-1695.
[30]	McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy[J]. Cancer, 2020, 126(17): 3950-3960.
[31]	Takemura K, Ernst MS, Navani V, et al. Characterization of patients with metastatic renal cell carcinoma undergoing deferred, upfront, or no cytoreductive nephrectomy in the era of combination immunotherapy: results from the international metastatic renal cell carcinoma database consortium[J]. Eur Urol Oncol, 2023: S2588-9311(23)00217-1.
[32]	Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial[J]. JAMA Oncol, 2019, 5(2): 164-170.
[33]	Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition[J]. N Engl J Med, 2017, 377(25): 2500-2501.
[34]	MacFarlane AW 4th, Jillab M, Plimack ER, et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection[J]. Cancer Immunol Res, 2014, 2(4): 320-331.
[35]	Justine P, Ava S, Kevin H, et al. Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC)[J]. J Clin Oncol, 2022, 40(6): 334.
[36]	Bhindi B, Habermann EB, Mason RJ, et al. Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma[J]. J Urol, 2018, 200(3): 528-534.

Please choose a citation manager

Content to export